This article explores insights from Richmond-area therapists on Ketamine-Assisted Psychotherapy (KAP) and EMDR therapy, focusing on their applications in treating trauma, CPTSD, and mental health ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...